262 related articles for article (PubMed ID: 11790777)
1. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency.
Yagyu H; Lutz EP; Kako Y; Marks S; Hu Y; Choi SY; Bensadoun A; Goldberg IJ
J Biol Chem; 2002 Mar; 277(12):10037-43. PubMed ID: 11790777
[TBL] [Abstract][Full Text] [Related]
2. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.
Weinstock PH; Bisgaier CL; Aalto-Setälä K; Radner H; Ramakrishnan R; Levak-Frank S; Essenburg AD; Zechner R; Breslow JL
J Clin Invest; 1995 Dec; 96(6):2555-68. PubMed ID: 8675619
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia.
Shimada M; Shimano H; Gotoda T; Yamamoto K; Kawamura M; Inaba T; Yazaki Y; Yamada N
J Biol Chem; 1993 Aug; 268(24):17924-9. PubMed ID: 8349676
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice.
van der Hoogt CC; Berbée JF; Espirito Santo SM; Gerritsen G; Krom YD; van der Zee A; Havekes LM; van Dijk KW; Rensen PC
Biochim Biophys Acta; 2006 Feb; 1761(2):213-20. PubMed ID: 16478678
[TBL] [Abstract][Full Text] [Related]
5. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis.
Goudriaan JR; Espirito Santo SM; Voshol PJ; Teusink B; van Dijk KW; van Vlijmen BJ; Romijn JA; Havekes LM; Rensen PC
J Lipid Res; 2004 Aug; 45(8):1475-81. PubMed ID: 15145981
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis.
Boisfer E; Lambert G; Atger V; Tran NQ; Pastier D; Benetollo C; Trottier JF; Beaucamps I; Antonucci M; Laplaud M; Griglio S; Chambaz J; Kalopissis AD
J Biol Chem; 1999 Apr; 274(17):11564-72. PubMed ID: 10206963
[TBL] [Abstract][Full Text] [Related]
7. Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma.
Levak-Frank S; Weinstock PH; Hayek T; Verdery R; Hofmann W; Ramakrishnan R; Sattler W; Breslow JL; Zechner R
J Biol Chem; 1997 Jul; 272(27):17182-90. PubMed ID: 9202040
[TBL] [Abstract][Full Text] [Related]
8. Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center.
Salinelli S; Lo JY; Mims MP; Zsigmond E; Smith LC; Chan L
J Biol Chem; 1996 Sep; 271(36):21906-13. PubMed ID: 8702993
[TBL] [Abstract][Full Text] [Related]
9. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
[TBL] [Abstract][Full Text] [Related]
10. LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice.
Tacken PJ; Teusink B; Jong MC; Harats D; Havekes LM; van Dijk KW; Hofker MH
J Lipid Res; 2000 Dec; 41(12):2055-62. PubMed ID: 11108739
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro.
Medh JD; Bowen SL; Fry GL; Ruben S; Andracki M; Inoue I; Lalouel JM; Strickland DK; Chappell DA
J Biol Chem; 1996 Jul; 271(29):17073-80. PubMed ID: 8663292
[TBL] [Abstract][Full Text] [Related]
12. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure.
Liang K; Oveisi F; Vaziri ND
Kidney Int; 1998 Mar; 53(3):626-30. PubMed ID: 9507207
[TBL] [Abstract][Full Text] [Related]
13. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI.
Hu L; van der Hoogt CC; Espirito Santo SM; Out R; Kypreos KE; van Vlijmen BJ; Van Berkel TJ; Romijn JA; Havekes LM; van Dijk KW; Rensen PC
J Lipid Res; 2008 Jul; 49(7):1553-61. PubMed ID: 18367731
[TBL] [Abstract][Full Text] [Related]
14. Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.
Tacken PJ; Beer FD; Vark LC; Havekes LM; Hofker MH; Willems Van Dijk K
Biochem J; 2000 Apr; 347(Pt 2):357-61. PubMed ID: 10749663
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice.
Zsigmond E; Kobayashi K; Tzung KW; Li L; Fuke Y; Chan L
Hum Gene Ther; 1997 Nov; 8(16):1921-33. PubMed ID: 9382958
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation.
Takahashi S
J Atheroscler Thromb; 2017 Jun; 24(6):552-559. PubMed ID: 28428482
[TBL] [Abstract][Full Text] [Related]
17. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.
Argraves KM; Battey FD; MacCalman CD; McCrae KR; Gåfvels M; Kozarsky KF; Chappell DA; Strauss JF; Strickland DK
J Biol Chem; 1995 Nov; 270(44):26550-7. PubMed ID: 7592875
[TBL] [Abstract][Full Text] [Related]
18. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase.
Excoffon KJ; Liu G; Miao L; Wilson JE; McManus BM; Semenkovich CF; Coleman T; Benoit P; Duverger N; Branellec D; Denefle P; Hayden MR; Lewis ME
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2532-9. PubMed ID: 9409224
[TBL] [Abstract][Full Text] [Related]
19. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.
Schaap FG; Rensen PC; Voshol PJ; Vrins C; van der Vliet HN; Chamuleau RA; Havekes LM; Groen AK; van Dijk KW
J Biol Chem; 2004 Jul; 279(27):27941-7. PubMed ID: 15090553
[TBL] [Abstract][Full Text] [Related]
20. Effect of diet on adipose tissue and skeletal muscle VLDL receptor and LPL: implications for obesity and hyperlipidemia.
Roberts CK; Barnard RJ; Liang KH; Vaziri ND
Atherosclerosis; 2002 Mar; 161(1):133-41. PubMed ID: 11882325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
